6-氨基-1-苯磺酰基-1H-吲唑 | 1046453-98-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-氨基-1-苯磺酰基-1H-吲唑
• 英文名称: 6-amino-1-benzenesulfonyl-1H-indazole
• CAS: 1046453-98-8
• 化学式: C₁₃H₁₁N₃O₂S
• 分子量: 273.315
• InChiKey: OOVZGKFFMIERJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.86
• 重原子数：
  19.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.98
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  6-氨基-1-苯磺酰基-1H-吲唑 、 异硫氰酸甲酯 以 四氢呋喃 为溶剂， 以92%的产率得到1-benzenesulfonyl-6-(3-methyl-thioureido)-1H-indazole
  参考文献：
  名称：

  An expedient, regioselective synthesis of novel 2-alkylamino- and 2-alkylthiothiazolo[5,4-e]- and -[4,5-g]indazoles and their anticancer potential

  摘要：

  Several novel 2-alkylamino- and 2-alkylthiothiazolo[5,4-e]- and -[4,5-g]indazoles and their 6-alkyl and 8-alkyl derivatives have been synthesised in high overall yields starting from 5-nitro and 6-nitro-indazoles in a three-step route involving the regioselective cyclisation of thioureidoindazoles and indazolyl dithiocarbamates as the key steps. Some assorted thiazoloindazoles have been screened for anticancer properties, which demonstrated the anticancer potential of at least one product, justifying its further follow-up. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.05.009
• 作为产物：
  描述：

  1-benzenesulfonyl-6-nitro-1H-indazole 在 palladium on activated charcoal 肼 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以93%的产率得到6-氨基-1-苯磺酰基-1H-吲唑
  参考文献：
  名称：

  An expedient, regioselective synthesis of novel 2-alkylamino- and 2-alkylthiothiazolo[5,4-e]- and -[4,5-g]indazoles and their anticancer potential

  摘要：

  Several novel 2-alkylamino- and 2-alkylthiothiazolo[5,4-e]- and -[4,5-g]indazoles and their 6-alkyl and 8-alkyl derivatives have been synthesised in high overall yields starting from 5-nitro and 6-nitro-indazoles in a three-step route involving the regioselective cyclisation of thioureidoindazoles and indazolyl dithiocarbamates as the key steps. Some assorted thiazoloindazoles have been screened for anticancer properties, which demonstrated the anticancer potential of at least one product, justifying its further follow-up. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.05.009